GlycoMimetics, Inc. Presents Data On Its E-Selectin Antagonist At American Association for Cancer Research Annual Meeting 2014

GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that three posters of preclinical research study data for its E-Selectin antagonist (GMI-1271) were highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2014. GlycoMimetics is initially exploring the clinical use of the drug to treat acute myeloid leukemia (AML). The company plans to initiate a Phase 1 trial of GMI-1271 in healthy volunteers during the second quarter of 2014.

Help employers find you! Check out all the jobs and post your resume.